Chronic myeloid leukemia and interferon-α

• Verfasst von: Bonifazi, Francesca [VerfasserIn]
• Verfasst von: Vivo, Antonio de [VerfasserIn]
• Verfasst von: Rosti, Gianantonio [VerfasserIn]
• Verfasst von: Guilhot, François [VerfasserIn]
• Verfasst von: Guilhot, Joëlle [VerfasserIn]
• Verfasst von: Trabacchi, Elena [VerfasserIn]
• Verfasst von: Hehlmann, Rüdiger [VerfasserIn]
• Verfasst von: Hochhaus, Andreas [VerfasserIn]
• Verfasst von: Shepherd, Patricia C. A. [VerfasserIn]
• Verfasst von: Steegmann, Juan Luis [VerfasserIn]
• Verfasst von: Kluin-Nelemans, Hanneke C. [VerfasserIn]
• Verfasst von: Thaler, Josef [VerfasserIn]
• Verfasst von: Simonsson, Bengt [VerfasserIn]
• Verfasst von: Louwagie, Andries [VerfasserIn]
• Verfasst von: Reiffers, Josy [VerfasserIn]
• Verfasst von: Mahon, François Xavier [VerfasserIn]
• Verfasst von: Montefusco, Enrico [VerfasserIn]
• Verfasst von: Alimena, Giuliana [VerfasserIn]
• Verfasst von: Hasford, Joerg [VerfasserIn]
• Verfasst von: Richards, Sue [VerfasserIn]
• Verfasst von: Saglio, Giuseppe [VerfasserIn]
• Verfasst von: Testoni, Nicoletta [VerfasserIn]
• Verfasst von: Martinelli, Giovanni [VerfasserIn]
• Verfasst von: Tura, Sante [VerfasserIn]
• Verfasst von: Baccarani, Michele [VerfasserIn]
• Titel: Chronic myeloid leukemia and interferon-α
• Titelzusatz: a study of complete cytogenetic responders
• Verf.angabe: Francesca Bonifazi, Antonio de Vivo, Gianantonio Rosti, François Guilhot, Joëlle Guilhot, Elena Trabacchi, Rüdiger Hehlmann, Andreas Hochhaus, Patricia C.A. Shepherd, Juan Luis Steegmann, Hanneke C. Kluin-Nelemans, Josef Thaler, Bengt Simonsson, Andries Louwagie, Josy Reiffers, François Xavier Mahon, Enrico Montefusco, Giuliana Alimena, Joerg Hasford, Sue Richards, Giuseppe Saglio, Nicoletta Testoni, Giovanni Martinelli, Sante Tura, and Michele Baccarani, for the European Study Group on Interferon in Chronic Myeloid Leukemia
• E-Jahr: 2001
• Jahr: November 15, 2001
• Umfang: 8 S.
• Fussnoten: Gesehen am 18.05.2022
• Titel Quelle: Enthalten in: Blood
• Ort Quelle: Washington, DC : American Society of Hematology, 1946
• Jahr Quelle: 2001
• Band/Heft Quelle: 98(2001), 10, Seite 3074-3081
• ISSN Quelle: 1528-0020
• DOI: doi:10.1182/blood.V98.10.3074
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 180247840X

Abstract

Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of chronic myeloid leukemia (CML) with interferon-α (IFN-α), but CCgRs are rare. The mean CCgR rate is 13%, in a range of 5% to 33%. A collaborative study of 9 European Union countries has led to the collection of data on 317 patients who were first seen between 1983 and 1997 and achieved CCgRs with IFN-α alone or in combination with hydroxyurea. The median time to first CCgR was 19 months (95% CI, 17-21; range, 3-84 months). At last contact, 212 patients were still alive and in continuous CCgR; 105 patients had lost CCgR, but 53% of them were still alive and in chronic phase. IFN-α treatment was discontinued permanently in 23 cases for response loss, in 36 cases for chronic toxicity (15 are still in unmaintained continuous CCgR), and in 8 cases because it was believed that treatment was no longer necessary (7 of these 8 patients are still in unmaintained continuous CCgR). The 10-year survival rate from first CCgR is 72% (95% CI, 62%-82%) and is related to the risk profile. High-risk patients lost CCgR more frequently and more rapidly and none survived more than 10 years. Low-risk patients survived much longer (10-year survival probability 89% for Sokal low risk and 81% for Euro low risk). These data point out that a substantial long-term survival in CCgRs is restricted mainly to low-risk and possibly intermediate-risk patients and occurs significantly less often in high-risk patients.